Advanced Artificial Pancreas Systems to Enable Fully Automated Glycemic Control in Type 1 Diabetes Mellitus
先进的人工胰腺系统可实现 1 型糖尿病的全自动血糖控制
基本信息
- 批准号:10488207
- 负责人:
- 金额:$ 67.18万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-09-12 至 2026-07-31
- 项目状态:未结题
- 来源:
- 关键词:AddressAdverse eventAlgorithm DesignAlgorithmsArchitectureArtificial PancreasAutomationBehaviorBlood GlucoseBolus InfusionCarbohydratesClinicalClinical ResearchClinical TrialsComputer SimulationDataDatabasesDeteriorationDevicesDiabetes MellitusDisease ManagementDoseEatingEcosystemExposure toFDA approvedFormulationFoundationsGlucoseGlycosylated hemoglobin AHomeHourHybridsHyperglycemiaHypoglycemiaInsulinInsulin-Dependent Diabetes MellitusKineticsLawsLegal patentLengthManualsMeasuresMedical DeviceOutcomeOutpatientsParticipantPatient Outcomes AssessmentsPatientsPatternPattern RecognitionPerformancePersonsPilot ProjectsRandomizedRandomized Controlled TrialsResearchRiskSafetySourceSpeedSupervisionSystemTechnologyTestingTherapeuticTimeTranslationsWorkalgorithm developmentanalogattenuationbasal insulinburden of illnessdesignglycemic controlimprovedin silicoindexingnovelpredictive modelingsatisfactionsubcutaneoussuccesstool
项目摘要
PROJECT ABSTRACT
Despite advancements in automated insulin delivery systems that demonstrate superior glycemic
outcomes, challenging clinical issues remain with the continued need for accurate carbohydrate
counting and meal announcement combined with slow-acting subcutaneous insulin that
contribute to repeated occurrences of postprandial hyperglycemia. This clinical gap in glycemic
control is addressed by the proposed project. We intend to leverage our existing advancements
in pattern recognition and anticipation to refine and test a fully automated closed-loop system that
does not require meal announcements. This system is unique in that it relies on pattern
recognition, particularly surrounding meals, in an anticipatory manner so that insulin action is
taken in advance of an expected meal rather than the predominantly reactive solutions that are
often proposed. We intend to further test and tune this system within the context of accelerated
insulins to further improve glycemic outcomes and remove barriers to use of these systems by
lowering burden of disease management.
We have already developed the foundational tools needed for a fully automated closed-loop and
will plan for further refinement by leveraging data from our accumulated clinical studies database.
We plan to conduct 2 pilots studies followed by a larger, 7-month main study to evaluate the
following specific aims of this proposal:
1) We hypothesize that novel faster acting insulin analogs can be safely used to provide more
effective fully automated closed-loop control. Our first pilot will test the differences between Fiasp
and a novel formulation of aspart (AT247) in a supervised trial. This trial results will inform the
selection of the insulin used in the subsequent trials.
2) We hypothesize that, with a design adapted to these new insulin formulations, fully automated
closed-loop control is a valid clinical alternative to hybrid closed-loop systems, the current state-
of-the-art systems.
3) Lastly, we hypothesize that further adding glycemic disturbance anticipation (e.g. generally
surrounding meals) to this fully automated closed-loop control system will further improve
glycemic outcomes compared with a fully automated closed-loop system without disturbance
anticipation.
项目摘要
尽管自动胰岛素输送系统取得了进步,显示出优越的血糖水平
随着对准确碳水化合物的持续需求,挑战性的临床问题仍然存在
计数和进餐通知结合慢效皮下胰岛素
导致餐后高血糖反复发生。这种血糖的临床差距
拟议项目解决了控制问题。我们打算利用我们现有的进步
在模式识别和预期中完善和测试全自动闭环系统
不需要用餐公告。该系统的独特之处在于它依赖于模式
以预期的方式识别,特别是围绕膳食,以便胰岛素作用
在预计进餐之前服用,而不是主要反应性的解决方案
经常提出。我们打算在加速的背景下进一步测试和调整这个系统
胰岛素进一步改善血糖结果并消除使用这些系统的障碍
减轻疾病管理负担。
我们已经开发了全自动闭环和
将利用我们积累的临床研究数据库中的数据来计划进一步完善。
我们计划进行 2 项试点研究,然后进行一项更大规模的、为期 7 个月的主要研究来评估
该提案的具体目标如下:
1) 我们假设新型速效胰岛素类似物可以安全地用于提供更多作用
有效的全自动闭环控制。我们的第一个试点将测试 Fiasp 之间的差异
以及一项监督试验中的天冬氨酸(AT247)新配方。该试验结果将告知
选择后续试验中使用的胰岛素。
2) 我们假设,通过适应这些新胰岛素配方的设计,完全自动化
闭环控制是混合闭环系统的有效临床替代方案,目前的状态
最先进的系统。
3)最后,我们假设进一步增加血糖紊乱预期(例如,通常
周围的饭菜)到这个全自动闭环控制系统将进一步改善
与无干扰的全自动闭环系统相比,血糖结果
预期。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
MARC D BRETON其他文献
MARC D BRETON的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('MARC D BRETON', 18)}}的其他基金
Advanced Artificial Pancreas Systems to Enable Fully Automated Glycemic Control in Type 1 Diabetes Mellitus
先进的人工胰腺系统可实现 1 型糖尿病的全自动血糖控制
- 批准号:
10676903 - 财政年份:2021
- 资助金额:
$ 67.18万 - 项目类别:
Advanced Artificial Pancreas Systems to Enable Fully Automated Glycemic Control in Type 1 Diabetes Mellitus
先进的人工胰腺系统可实现 1 型糖尿病的全自动血糖控制
- 批准号:
10276560 - 财政年份:2021
- 资助金额:
$ 67.18万 - 项目类别:
Translation of the UVA Advanced Automated Insulin Delivery Systems to Clinical Care in Young Children: Glycemic Control, Regulatory Acceptance and Optimization of Day to Day Use
UVA 先进自动胰岛素输送系统在幼儿临床护理中的应用:血糖控制、监管接受和日常使用优化
- 批准号:
10474818 - 财政年份:2021
- 资助金额:
$ 67.18万 - 项目类别:
Artificial Pancreas - Adolescent Physiology and Psychology Longitudinal Evaluation (A.P. APPLE)
人工胰腺 - 青少年生理学和心理学纵向评估 (A.P. APPLE)
- 批准号:
10381710 - 财政年份:2020
- 资助金额:
$ 67.18万 - 项目类别:
Translation of the UVA Advanced Automated Insulin Delivery Systems to Clinical Care in Young Children: Glycemic Control, Regulatory Acceptance and Optimization of Day to Day Use
UVA 先进自动胰岛素输送系统在幼儿临床护理中的应用:血糖控制、监管接受和日常使用优化
- 批准号:
10265602 - 财政年份:2020
- 资助金额:
$ 67.18万 - 项目类别:
Translation of the UVA Advanced Automated Insulin Delivery Systems to Clinical Care in Young Children: Glycemic Control, Regulatory Acceptance and Optimization of Day to Day Use
UVA 先进自动胰岛素输送系统在幼儿临床护理中的应用:血糖控制、监管接受和日常使用优化
- 批准号:
10470808 - 财政年份:2020
- 资助金额:
$ 67.18万 - 项目类别:
Artificial Pancreas - Adolescent Physiology and Psychology Longitudinal Evaluation (A.P. APPLE)
人工胰腺 - 青少年生理学和心理学纵向评估 (A.P. APPLE)
- 批准号:
10597623 - 财政年份:2020
- 资助金额:
$ 67.18万 - 项目类别:
Models, signals, and distributed bio-behavioral control of exercise in diabetes
糖尿病运动的模型、信号和分布式生物行为控制
- 批准号:
8971447 - 财政年份:2015
- 资助金额:
$ 67.18万 - 项目类别:
HYPOGLYCEMIA PREVENTION AFTER EXERCISE IN ADOLESCENT T1DM
青少年 T1DM 运动后低血糖的预防
- 批准号:
8167207 - 财政年份:2010
- 资助金额:
$ 67.18万 - 项目类别:
FEASIBILITY STUDY OF A MODULAR CONTROL TO RANGE SYSTEM IN T1DM
T1DM 测距系统模块化控制的可行性研究
- 批准号:
8167201 - 财政年份:2010
- 资助金额:
$ 67.18万 - 项目类别:
相似海外基金
Planar culture of gastrointestinal stem cells for screening pharmaceuticals for adverse event risk
胃肠道干细胞平面培养用于筛选药物不良事件风险
- 批准号:
10707830 - 财政年份:2023
- 资助金额:
$ 67.18万 - 项目类别:
Hospital characteristics and Adverse event Rate Measurements (HARM) Evaluated over 21 years.
医院特征和不良事件发生率测量 (HARM) 经过 21 年的评估。
- 批准号:
479728 - 财政年份:2023
- 资助金额:
$ 67.18万 - 项目类别:
Operating Grants
Analysis of ECOG-ACRIN adverse event data to optimize strategies for the longitudinal assessment of tolerability in the context of evolving cancer treatment paradigms (EVOLV)
分析 ECOG-ACRIN 不良事件数据,以优化在不断发展的癌症治疗范式 (EVOLV) 背景下纵向耐受性评估的策略
- 批准号:
10884567 - 财政年份:2023
- 资助金额:
$ 67.18万 - 项目类别:
AE2Vec: Medical concept embedding and time-series analysis for automated adverse event detection
AE2Vec:用于自动不良事件检测的医学概念嵌入和时间序列分析
- 批准号:
10751964 - 财政年份:2023
- 资助金额:
$ 67.18万 - 项目类别:
Understanding the real-world adverse event risks of novel biosimilar drugs
了解新型生物仿制药的现实不良事件风险
- 批准号:
486321 - 财政年份:2022
- 资助金额:
$ 67.18万 - 项目类别:
Studentship Programs
Pediatric Adverse Event Risk Reduction for High Risk Medications in Children and Adolescents: Improving Pediatric Patient Safety in Dental Practices
降低儿童和青少年高风险药物的儿科不良事件风险:提高牙科诊所中儿科患者的安全
- 批准号:
10676786 - 财政年份:2022
- 资助金额:
$ 67.18万 - 项目类别:
Pediatric Adverse Event Risk Reduction for High Risk Medications in Children and Adolescents: Improving Pediatric Patient Safety in Dental Practices
降低儿童和青少年高风险药物的儿科不良事件风险:提高牙科诊所中儿科患者的安全
- 批准号:
10440970 - 财政年份:2022
- 资助金额:
$ 67.18万 - 项目类别:
Improving Adverse Event Reporting on Cooperative Oncology Group Trials
改进肿瘤学合作组试验的不良事件报告
- 批准号:
10642998 - 财政年份:2022
- 资助金额:
$ 67.18万 - 项目类别:
Planar culture of gastrointestinal stem cells for screening pharmaceuticals for adverse event risk
胃肠道干细胞平面培养用于筛选药物不良事件风险
- 批准号:
10482465 - 财政年份:2022
- 资助金额:
$ 67.18万 - 项目类别:
Expanding and Scaling Two-way Texting to Reduce Unnecessary Follow-Up and Improve Adverse Event Identification Among Voluntary Medical Male Circumcision Clients in the Republic of South Africa
扩大和扩大双向短信,以减少南非共和国自愿医疗男性包皮环切术客户中不必要的后续行动并改善不良事件识别
- 批准号:
10191053 - 财政年份:2020
- 资助金额:
$ 67.18万 - 项目类别: